WO2002098915A3 - Compositions and methods for detecting or regulating cholesteryl ester transfer protein - Google Patents

Compositions and methods for detecting or regulating cholesteryl ester transfer protein Download PDF

Info

Publication number
WO2002098915A3
WO2002098915A3 PCT/EP2002/006228 EP0206228W WO02098915A3 WO 2002098915 A3 WO2002098915 A3 WO 2002098915A3 EP 0206228 W EP0206228 W EP 0206228W WO 02098915 A3 WO02098915 A3 WO 02098915A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulating
compositions
detecting
methods
transfer protein
Prior art date
Application number
PCT/EP2002/006228
Other languages
French (fr)
Other versions
WO2002098915A2 (en
Inventor
Jamila Najib-Fruchart
Zouher Majd
Original Assignee
Genfit
Jamila Najib-Fruchart
Zouher Majd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit, Jamila Najib-Fruchart, Zouher Majd filed Critical Genfit
Priority to AU2002325827A priority Critical patent/AU2002325827A1/en
Publication of WO2002098915A2 publication Critical patent/WO2002098915A2/en
Publication of WO2002098915A3 publication Critical patent/WO2002098915A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to compositions and methods for detecting or regulating Cholesteryl Ester Transfer Protein ('CETP'). This invention also relates to synthetic CETP peptides, corresponding antibodies, kits comprising the same, and their use to detect, quantify and/or monitor CETP levels in a sample. The above compounds and kits can also be used to modulate CETP levels or activity in vitro or in vivo, and to regulate lipid metabolism in a subject.
PCT/EP2002/006228 2001-06-07 2002-06-06 Compositions and methods for detecting or regulating cholesteryl ester transfer protein WO2002098915A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002325827A AU2002325827A1 (en) 2001-06-07 2002-06-06 Compositions and methods for detecting or regulating cholesteryl ester transfer protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01401468 2001-06-07
EP01401468.2 2001-06-07

Publications (2)

Publication Number Publication Date
WO2002098915A2 WO2002098915A2 (en) 2002-12-12
WO2002098915A3 true WO2002098915A3 (en) 2003-11-20

Family

ID=8182759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006228 WO2002098915A2 (en) 2001-06-07 2002-06-06 Compositions and methods for detecting or regulating cholesteryl ester transfer protein

Country Status (2)

Country Link
AU (1) AU2002325827A1 (en)
WO (1) WO2002098915A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
EP2532359A1 (en) * 2011-06-10 2012-12-12 Affiris AG CETP fragments

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06169793A (en) * 1992-12-02 1994-06-21 Eiken Chem Co Ltd Monoclonal antibody
WO1996034888A1 (en) * 1995-05-01 1996-11-07 T Cell Sciences, Inc. Modulation of cholesteryl ester transfer protein (cetp) activity
JPH0977798A (en) * 1995-09-08 1997-03-25 Wako Pure Chem Ind Ltd Antibody resistance to cholesteryl ester transfer protein
WO1999015655A1 (en) * 1997-09-19 1999-04-01 Monsanto Company Dna vaccination against cholesterol ester transfer protein in the treatment of atherosclerosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06169793A (en) * 1992-12-02 1994-06-21 Eiken Chem Co Ltd Monoclonal antibody
WO1996034888A1 (en) * 1995-05-01 1996-11-07 T Cell Sciences, Inc. Modulation of cholesteryl ester transfer protein (cetp) activity
JPH0977798A (en) * 1995-09-08 1997-03-25 Wako Pure Chem Ind Ltd Antibody resistance to cholesteryl ester transfer protein
WO1999015655A1 (en) * 1997-09-19 1999-04-01 Monsanto Company Dna vaccination against cholesterol ester transfer protein in the treatment of atherosclerosis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199722, Derwent World Patents Index; Class B04, AN 1997-241756, XP002240081 *
EVANS ET AL: "INHBITION OF CHOLESTERYL ESTER TRANSFER PROTEIN IN NORMOCHOLESTEROLEMIC AND HYPOCHOLESTEROLEMIC HAMSTERS: EFFECTS ON HDL SUBSPECIES, QUANTITY, AND APOLIPOPROTEIN DISTRIBUTION", JOURNAL OF LIPID RESEARCH, BETHESDA, MD, US, vol. 35, 1994, pages 1634 - 1645, XP002090148, ISSN: 0022-2275 *
GUYARD-DANGREMONT V ET AL: "IMMUNOCHEMICAL EVIDENCE THAT CHOLESTERYL ESTER TRANSFER PROTEIN ANDBACTERICIDAL/PERMEABILITY-INCREASING PROTEIN SHARE A SIMILAR TERTIARY STRUCTURE", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 8, no. 11, November 1999 (1999-11-01), pages 2392 - 2398, XP001016293, ISSN: 0961-8368 *
MEZDOUR H, KORA I, PARRA HJ, TARTAR A, MARCEL YL, FRUCHART JC: "Two-site enzyme immunoassay of cholesteryl ester transfer protein with monoclonal and oligoclonal antibodies", CLIN. CHEM., vol. 40, no. 4, 1994, pages 593 - 597, XP002943825 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 501 (C - 1251) 20 September 1994 (1994-09-20) *
ROY PATRICE ET AL: "Structure-function relationships of human cholesteryl ester transfer protein: Analysis using monoclonal antibodies.", JOURNAL OF LIPID RESEARCH, vol. 37, no. 1, 1996, pages 22 - 34, XP002240080, ISSN: 0022-2275 *

Also Published As

Publication number Publication date
AU2002325827A1 (en) 2002-12-16
WO2002098915A2 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
WO1999052425A3 (en) Body composition analyzer with trend display
WO2004000884A3 (en) Compositions and methods for apo-b48 and apo-b100 assay
BR0009323A (en) Human antibodies that bind human il-12 and methods for production
ATE261069T1 (en) WEAR SENSOR FOR THE BRAKE ELEMENT OF A VEHICLE
WO2001082793A3 (en) Method and device for testing a sample of fresh whole blood
AU2003253784A1 (en) Peptides from the e2, e6 and e7 proteins of human papillomaviruses 16 and 18 for detecting and/or diagnosing cervical and other cancers
AU7669898A (en) Method for assessing disposable absorbent articles
NZ334518A (en) Homocysteine desulphurase from the protozoan trichomonas vaginalis
AU2001239544A1 (en) Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
CA2366514A1 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
WO2002098915A3 (en) Compositions and methods for detecting or regulating cholesteryl ester transfer protein
CA2407760A1 (en) Methods for diagnosis of low grade astrocytoma
AU5449099A (en) Novel receptor protein and method for diagnosing inflammatory diseases by using the same
WO2002072872A3 (en) System for screening fatty acid transport inhibitors, methods of use and modulators identified thereby
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
EP1291085A3 (en) Test strip compression element
AU2001259476A1 (en) Assay for detecting, measuring and monitoring the activities and concentrations of proteins and methods of use thereof
WO2002098919A3 (en) Method for apo ciii measurement in apob and non apob containing particles
CA2384170A1 (en) Cgmp-visualizing probe and method of detecting and quantifying cgmp by using the same
WO2003023056A3 (en) Specific markers for multiple sclerosis
WO2005019471A3 (en) Periostin-like factor: compositions and methods for making and using the same
Smith et al. A new creativity test.
AU1690899A (en) Method for testing crohn's disease and testing kit therefor
NO983984L (en) Disintegrin metalloprotease and its use
WO2004099784A3 (en) Method for determining a tissue degradation process by detection of fibromodulin neoepitopes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP